BackAIM ImmunoTech Overview

AIM ImmunoTech Long Term Debt

Track AIM ImmunoTech's long-term debt ($41K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$41000.00
↓ 85.46% YoYΔ $-241000.00 vs prior year quarter

Peer trimmed avg / median

Loading

AIM ImmunoTech Long Term Debt History

Loading

AIM ImmunoTech vs. peers: Long Term Debt Comparison

Loading

AIM ImmunoTech Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

AIM ImmunoTech (AIM) FAQ

The latest long-term debt for AIM is $41K as of June 2026. That compares with $280K in the prior-year period — down 85.5% year over year. Investors often review this figure alongside AIM ImmunoTech's historical trend and sector peers before judging valuation or financial health.

Over the past year, AIM's long-term debt moved from $280K to $41K — a 85.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AIM ImmunoTech's operating scale or balance-sheet position.

A long-term debt figure of $41K for AIM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AIM's long-term debt ($41K), review year-over-year change from $280K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack AIM ImmunoTech's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.